

KATHARINA ELISABETH BLANKART (née FISCHER)

Assistant Professor of Empirical Health Economics

THIRD PARTY FUNDING

RESEARCH FUNDING – COMPETITIVE GRANTS

Period	Role	Source	Title	Field	Collaborator / Countries	Length
21-23	Co-PI	German Research Foundation (DFG)*	Causes and consequences of drug shortages	Econ / Policy	Hertie School Germany	2 years
20 – 21	Co-PI	German Academic Exchange Service (DAAD PPP Program)*	Advancing machine-learning methods to benchmark health care expenditure profiles and technology adoption to inform health care policy and practice	Econ / Policy	Monash University, Australia	2 years
20 - 24	Project partner	Leibniz Foundation*	Leibniz Science Campus Ruhr: Health-care challenges in regions with declining and ageing populations, sub-project 3: Fragmentation of health care, health care utilization and health outcomes	Econ	University of Duisburg-Essen, RWI Essen, Germany; Tilburg University, NL	4 years
20 - 24	Co-Investigator, MC	European Cooperation in Science and Technology (COST)*	CA19132 - European Network to Advance Best practices & technology on medication adherence	Interdisciplinary	39 European countries, PI at University of Groningen, NL	4 years
20 – 21	Co-Investigator	WWZ Forum*	Drug Shortages and their Consequences on Quality and Cost of Treatment	Econ	University of Basel, Switzerland*	16 month years
19 – 22	PI	Deutsche Krebshilfe (German Cancer Aid)*	Determinants of innovative capacity and standardization in specialized cancer care	Health Services Research	Deutsche Krebsgesellschaft, Germany	3 years
16 – 21	Project lead (since 2019)	German Ministry of Education and Research (BMBF)*	CINCH Health Economics Center, Junior Research Group Empirical Analysis of Competition in Health Care Markets	Econ	University of Duisburg-Essen, Germany	4 years
17 – 18	PI	Central Research Institute of Ambulatory Health Care (Zi)*	The impact of regulation at the regional level using the example of biosimilars	Health Services Research	-	1 year
14 – 17	Co-PI	German Research Foundation (DFG)*	Early benefit assessment of innovative pharmaceuticals according to AMNOG in Germany: empirical analysis of the decision-making process	Policy/Mgmt	University of Hamburg, Germany	2.5 years
12 – 16	Project lead	German Ministry of Education and Research (BMBF)*	Hamburg Center for Health Economics, Junior Research Group Pharmacoeconomics	Policy/Mgmt	University of Hamburg, Germany	4 years

RESEARCH FUNDING – NON-COMPETITIVE GRANTS

Period	Role	Source	Title	Field	Collaborator / Countries	Length
21-22	Co-Pi	Information Technology & Innovation Foundation, USA	The Adverse Effects of Imprecise (or Inappropriate) Medicine	Econ / Policy	Columbia University, United States	5 months
20– 21	Project partner	Data Literacy Education.NRW state level competition	DataCampus University of Duisburg-Essen	Interdiscipl inary	University of Duisburg- Essen, Germany	1 year
15 – 16	PI	DocMorris Online Pharmacy (ZurRose Group)	Medical care innovations, medication adherence, and health outcomes	Mgmt	Columbia Business School, USA	1 year

FUNDING FOR CONFERENCE TRAVELS

- German Academic Exchange Association (DAAD), travel stipend: 2012, 2013, 2014, and 2017
- German Health Economics Society (DGGÖ), travel stipend: 2017, 2018, and 2019
- Travel support for internationalization of research agenda, King’s College London (2017), Imperial College London (2022), Faculty of Economics & Business Administration, University of Duisburg-Essen

KATHARINA ELISABETH BLANKART (née FISCHER)

Assistant Professor of Empirical Health Economics

OUTREACH AND DISSEMINATION

ACTIVITIES AS GLOBAL HEALTH SYSTEM ADVISOR

Regular speaker and advisor at community, industry, and health system level to provide guidance how to develop governance systems for health technology assessment, technology adoption and implementation, selected collaborating partners:

- Roundtable Antibiotika, Switzerland
- German-American Chamber of Commerce, Midwest, USA
- Robert Bosch Stiftung, Germany
- International Association of Mutual Benefit Societies, European Union Level
- German-Peruvian Trade Chamber, Peru
- Global initiatives to advise communities in Ukraine, Germany and Ukraine
- Commonwealth Fund, USA
- Janssen-Cilag Co.Lab Disease Interception Initiative, Germany
- Bundesverband Managed Care (BMC e.V.), Germany

MEDIA COVERAGE AND PUBLIC TALKS

Social media outreach

- (1) Twitter: @katblankart
- (2) LinkedIn: <https://www.linkedin.com/in/katharina-blankart-33a95721/>

Media coverage

- (1) Das nationale Kompetenzzentrum der Gesundheitsökonomik. Monitor Versorgungsforschung; Available from: https://www.monitor-versorgungsforschung.de/Abstracts/Kurzfassungen_2022/MVF_01-22/MVF0122_Chinch
- (2) Expert opinion for journalists such as LA Times, Stern, Handelsblatt
- (3) Newer drugs improve health outcomes, lower care costs: study. Crain's New York Business. 2020.
- (4) Versorgung in Gefahr?: Diabetes-Gesellschaft schlägt Alarm. (2017, March 21). Handelsblatt.
- (5) Universität Duisburg-Essen: Wer schafft es auf den Gesundheitsmarkt? (2016, November 3). Duisburger Rundschau.

Public Talks

- (6) German-American Trade Chamber Midwest, panelist to discuss about the Future of Transatlantic Collaboration in Biopharma and MedTech, virtual, November 2021
- (7) Women in Economics, Fachschaft VWL, University of Bonn, virtual, May 2021
- (8) Projekt Neustart, Robert Bosch Stiftung, panelist (ThinkLab 5 – financing the German health care system) and moderator (ThinkLab 6 – governance and communication), September – December 2020
- (9) Access to medicines and value-based decision-making in Europe / Good health assessment practices in Europe – Case examples, Symposium der Deutsch-Peruanischen Außenhandelskammer, Lima, Peru, 26./27.9.2019, symposium talk
- (10) Die Gesundheit der Frau als Indikator für den Zustand der Gesellschaft. Women for Women, 10. April 2019, Berlin, public talk
- (11) Organisation of the German Health Care System, community based medicine project supported by Engagement Global, Kiev regional administration and Gemeinde Pullach im Isartal, Baryschiwka, Ukraine, November 2018